Sunday, February 5, 2023
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

Axcella terminates phase 2 trial, to focus on long COVID, NASH programs; R&D exec departs

by Euro Times
May 27, 2022
in Business
Reading Time: 2 mins read
A A
0
Home Business
Share on FacebookShare on Twitter


gorodenkoff/iStock by way of Getty Photos

Axcella Therapeutics (NASDAQ:AXLA) stated on Could 26 that it was suspending a section 2 trial of AXA1665 in Overt Hepatic Encephalopathy (OHE) and accomplished enrollment for a section 2a examine of AXA1125 to deal with lengthy COVID.

However the corporate must go on with its lengthy COVID and NASH applications with out its President of Analysis and Growth Alison Schecter, who stepped all the way down to pursue different alternatives, efficient instantly on Could 25, based on an SEC submitting by Axcella.

Axcella stated it made the choice to terminate the Part 2 trial in OHE — a dysfunction inflicting decline in mind perform because of extreme liver illness — and focus sources on the continuing Lengthy COVID and NASH (non-alcoholic steatohepatitis) applications.

The corporate famous that OHE is a uncommon illness of very ailing sufferers with enrollment challenges and the timelines to approval could be lengthy.

The trial was began in Q2 2021.

“We are going to discover partnerships and doubtlessly different indications for AXA1665,” stated Axcella President and CEO Invoice Hinshaw.

The corporate expects NASH trial interim information in late Q3 2022.

Lengthy COVID Trial:

Axcella famous that enrollment of 40 sufferers was accomplished within the Part 2a lengthy COVID trial and it expects topline information in early Q3.

“The execution of this Part 2a Lengthy COVID trial will considerably advance our pipeline and validate the effectiveness of EMMs to deal with multi-factorial illnesses,” stated Hinshaw.



Source link

Tags: AxcellaCoviddepartsexecFocusLongNashphaseProgramsterminatesTrial
Previous Post

Structural reforms essential for sustained, balanced, inclusive growth, RBI says in annual report

Next Post

Interview: Anna Fischer– NF Architects | by The Capital | The Capital | May, 2022

Related Posts

Hotel sector looks lucrative amid govt’s special focus on tourism, says ICICI Securities – suggests to buy these 2 stocks

by zee business
February 5, 2023
0

With the government’s special push to tourism and hospitality, the Hotel’s sector looks attractive and would see stupendous growth on...

Google Will Join the AI Wars, Pitting LaMDA Against ChatGPT

by Parmy Olson
February 5, 2023
0

MOUNTAIN VIEW, CALIFORNIA - FEBRUARY 02: A sign is posted in front of an office at Google headquarters on February...

IndiGo eyes expansion of international ops, eyes new routes

by Abhishek Law
February 4, 2023
0

IndiGo Airlines, the country’s largest carrier, is eyeing expansion of international operations as outbound travel picks up. Some of the...

From China to big sky: The balloon that unnerved the White House

by Euro Times
February 4, 2023
0

Star gazing is nothing unusual in Montana, where skies go on forever. But as...

US emerges as India’s top destination for goods exports during April-Dec 2022

by Euro Times
February 4, 2023
0

New Delhi: The US has emerged as India's top destination for merchandise exports during April-December this fiscal at USD 59.7...

U.S. warns Turkey on exports seen to boost Russia’s war effort By Reuters

by Reuters
February 4, 2023
0

By Jonathan Spicer ISTANBUL (Reuters) -The United States warned Turkey in recent days about the export to Russia of chemicals,...

Next Post

Interview: Anna Fischer– NF Architects | by The Capital | The Capital | May, 2022

Why Is It Getting Dumber?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

India is blocking over 230 betting and loan apps, many with ties to China • TechCrunch

February 5, 2023

Train carrying hazardous chemicals derails — RT World News

February 5, 2023

Foxconn’s January sales surge as China COVID disruption shaken off By Reuters

February 5, 2023

Hotel sector looks lucrative amid govt’s special focus on tourism, says ICICI Securities – suggests to buy these 2 stocks

February 5, 2023

Filecoin Creator Protocol Labs Announces Layoffs Amid Crypto Winter and Economic Downturn – Bitcoin News

February 5, 2023

Why This Recession is a HUGE Opportunity for Investors

February 5, 2023
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

India is blocking over 230 betting and loan apps, many with ties to China • TechCrunch

Train carrying hazardous chemicals derails — RT World News

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In